跳至主要内容
临床试验/NCT01231334
NCT01231334已完成4 期

A Study Comparing Aczone® Plus Differin® Versus Duac® Plus Differin® in Patients With Severe Facial Acne

Allergan0 个研究点目标入组 286 人开始时间: 2010年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
发起方
Allergan
入组人数
286
主要终点
Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12

研究概览

简要总结

A study comparing the topical application of Aczone® plus Differin® versus Duac® plus Differin® in patients with severe facial acne (facial acne vulgaris).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Single (Investigator)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
Female
接受健康志愿者

入选标准

  • Severe facial acne (acne vulgaris)

排除标准

  • History of significant anemia or hemolysis
  • History of enteritis (eg, regional enteritis, ulcerative colitis, pseudomembranous colitis, antibiotic-associated colitis)
  • History of lupus, rosacea, or seborrheic dermatitis

研究组 & 干预措施

Aczone® Gel 5% plus Differin® 0.3% Gel

Active Comparator

Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.

干预措施: Dapsone plus Adapalene (Drug)

Duac® Topical Gel plus Differin® 0.3% Gel

Active Comparator

Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks.

干预措施: Clindamycin/benzoyl peroxide plus Adapalene (Drug)

结局指标

主要结局

Percentage of Participants With at Least a One Point Decrease in the Global Acne Assessment Score (GAAS) at Week 12

时间窗: Baseline, Week 12

GAAS was conducted by the investigator at Baseline and Week 12. The patient's facial acne was evaluated on a 5 point scale 0=None (no evidence of acne), 1=Minimal (few lesions), 2=Mild (several to many non-inflammatory lesions; few inflammatory lesions), 3=Moderate (many lesions) to 4=Severe (Significant degree of inflammatory disease; papules/pustules present, few nodulo-cystic lesions; comedones may be present). Papules/nodules are round, solid elevations of the skin with no visible fluid. The percentage of participants with at least a one point decrease (improvement) in GAAS was calculated.

次要结局

  • Change From Baseline in Global Acne Assessment Score (GAAS) at Week 12(Baseline, Week 12)
  • Percentage of Participants at Week 12 Having at Least a One Point Decrease in Overall Disease Severity(Baseline, Week 12)
  • Percent Change From Baseline in Inflammatory Lesion Counts at Week 12(Baseline, Week 12)
  • Percent Change From Baseline in Non-inflammatory Lesion Counts at Week 12(Baseline, Week 12)
  • Percent Change From Baseline in Total Lesion Count at Week 12(Baseline, Week 12)
  • Percentage of Participants Demonstrating a ≥ 1 Category Increase in Tolerability From Baseline at Week 12(Baseline, Week 12)

研究者

发起方
Allergan
申办方类型
Industry
责任方
Sponsor

相似试验

A Study Comparing Aczone® Plus Differin® Versus... | 临床试验